Kiniksa Pharmaceuticals Ltd
NASDAQ:KNSA

Watchlist Manager
Kiniksa Pharmaceuticals Ltd Logo
Kiniksa Pharmaceuticals Ltd
NASDAQ:KNSA
Watchlist
Price: 42.52 USD -0.05% Market Closed
Market Cap: 3.2B USD

EV/EBIT
Enterprise Value to EBIT

74.8
Current
-26.9
Median
7
Industry
Higher than median
Higher than industry value
Created with Highcharts 11.4.8Jan '20July '20Jan '21July '21Jan '22July '22Jan '23July '23Jan '24July '24Jan '25July '250100200300400500
Nov-2025
74.8
EV/EBIT

Enterprise Value to EBIT (EV/EBIT) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s earnings before interest and taxes (EBIT). Considered one of the most frequently used multiples for comparisons among companies, the EV/EBIT multiple relies on operating income as the core driver of valuation.

EV/EBIT
74.8
=
Enterprise Value
2.9B USD
/
EBIT
38.2m USD
EBIT Growth EV/EBIT to Growth
BM
Kiniksa Pharmaceuticals Ltd
NASDAQ:KNSA
Average EV/EBIT: 31.7
74.8
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -195 170.3 N/A N/A
US
Abbvie Inc
NYSE:ABBV
23.5
30%
0.8
US
Amgen Inc
NASDAQ:AMGN
19
19%
1
US
Gilead Sciences Inc
NASDAQ:GILD
13
13%
1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
22.9
17%
1.3
US
E
Epizyme Inc
F:EPE
Negative Multiple: -557 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
19.4
12%
1.6
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -317.8 N/A N/A
AU
CSL Ltd
ASX:CSL
16.5
11%
1.5
NL
argenx SE
XBRU:ARGX
64.5
N/A N/A

EV/EBIT Forward Multiples

Forward EV/EBIT multiple is a version of the EV/EBIT ratio that uses forecasted EBIT for the EV/EBIT calculation. 1-Year, 2-Years, and 3-Years forwards use EBIT forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBIT
29.2
2-Years Forward
EV/EBIT
20.5
3-Years Forward
EV/EBIT
13.1

See Also

Summary
KNSA intrinsic value, competitors valuation, and company profile.
DCF Valuation
KNSA stock valuation using Discount Cash Flow valuation method.
Relative Valuation
KNSA stock valuation using valuation multiples.
Wall Street Estimates
KNSA price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
KNSA stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 299,800+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.